BOSTON--(BUSINESS WIRE)--PureTech Health plc – Half-Year Report.
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of the Tender Offer.
BOSTON--(BUSINESS WIRE)--Raju Kucherlapati, PhD, has been appointed Chair of the PureTech Board of Directors.
PureTech Health announces the initiation of a proposed tender offer of $100 million at 250 pence per Ordinary Share in Boston.
PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Conference Call on April 25, 2024 at 9:00 AM ET. Present on the call are Allison Mead Talbot, Bharatt Chowrira, Eric Elenko, and Chip Sherwood. Conference call participants include Miles Dixon from Peel Hunt and Lucy Codrington from Jefferies. Thank you for joining the PureTech Health 2023 Year End Financial Results Conference Call. Please note that this call is being recorded.
PureTech Health (PRTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
PureTech Health's founded entity, Karuna Therapeutics, has been successful in developing a therapeutic with an optimized profile. Karuna Therapeutics was acquired by BMY for $14 billion. PureTech's lead asset, LYT-100, may be a promising treatment for idiopathic pulmonary fibrosis (IPF) with a better tolerability profile compared to standard of care drugs.
PureTech Health PLC Sponsored ADR (PRTC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Shares in PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) PLC jumped 10% after it agreed a US$500mln royalty deal, US$100mln of which will be paid upfront. In the first half hour of trading the shares were up 21.49p at 224.49p.